Capturing the Value of R&D
Executive SummaryWorried about a likely gap in earnings, many drug companies want to increase the number of products in their pipelines. But such productivity driven strategies hav estrained development and commercialization resources while advancing mediocre compounds, compromising marketplace results. Yield-led companies have done far better, focusing on fewer, better products and devoting adequate resources to their development and launch.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.